Evaxion to Present New Data at AACR Annual Meeting, Two Abstracts Accepted for Presentation on Cancer Vaccine EVX-01 and Glioblastoma Treatment Strategy.

Evaxion A/S has announced two abstracts accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting. The abstracts focus on new biomarker and immunogenicity data for cancer vaccine EVX-01 and the use of Evaxion's AI-Immunology™ platform in developing a personalized cancer vaccine strategy for glioblastoma. The company will also participate in the AACR Oncology Industry Partnering event.